Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1516095 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL597023 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL183556 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL2996433 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL135214 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL27837624 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL27442081 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL1516096 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL5806394 | 0.94 | SLC34A1 (0.39) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL3454132 | 0.94 | SLC34A1 (0.39) | SLC34A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119008877-A | In-situ polymerization coated sodium ferric pyrophosphate composite material and preparation method and application thereof | 湖北三峡实验室 | 2024-11-22 | — | — | CN | claimed |
| CN-118833792-A | Lithium iron phosphate positive electrode material, and preparation method and application thereof | 曲靖市德方纳米科技有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-117581396-A | Lithium iron phosphate composite material and preparation method and application thereof | 广东邦普循环科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117106634-A | Intestinal synthetic flora of prawns and screening method and application thereof | 宁波大学 | 2023-11-24 | — | — | CN | claimed |
| CN-116925959-A | Directional construction method and application of efficient disease-resistant synthetic flora | 宁波大学 | 2023-10-24 | — | — | CN | claimed |
| CN-116230923-A | Carbon-coated sodium ferric pyrophosphate cathode material and preparation method and application thereof | 中国科学院过程工程研究所 | 2023-06-06 | — | — | CN | claimed |
| CN-114368737-A | High-compaction and high-capacity lithium iron phosphate positive electrode material and preparation method and application thereof | 东莞市创明电池技术有限公司 | 2022-04-19 | — | — | CN | claimed |
| WO-2021086416-A1 | OIL SWELLABLE MATERIAL FOR LOW TEMPERATURE LOST CIRCULATION MATERIAL APPLICATION | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-05-06 | — | — | WO | claimed |
| US-20210131201-A1 | OIL SWELLABLE MATERIAL FOR LOW TEMPERATURE LOST CIRCULATION MATERIAL APPLICATION | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-05-06 | — | — | US | claimed |
| CN-106566819-B | Gene cloning, expression, separation and purification method of low-temperature halophilic α -amylase | 哈尔滨工业大学（威海） | 2020-04-14 | — | — | CN | claimed |
| US-8308842-B2 | Pyrophoric iron nanoparticles and continuous processes for production thereof | XEROX CORPORATION (US) | 2012-11-13 | — | — | US | claimed |
| US-20120145947-A1 | PYROPHORIC IRON NANOPARTICLES AND CONTINUOUS PROCESSES FOR PRODUCTION THEREOF | XEROX CORPORATION (US) | 2012-06-14 | — | — | US | claimed |
| US-20260148984-A1 | IRON PHOSPHATE MATERIAL AND PREPARATION METHOD THEREFOR, CATHODE MATERIAL, CATHODE SHEET, AND SECONDARY BATTERY | HUBEI HONGRUN HIGH-TECH NEW MATERIALS CO., LTD. (CN) | 2026-05-28 | — | — | US | disclosed |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260092381-A1 | BIMETALLIC IRON-VANADIUM OXIDE ELECTROCATALYST FOR OXYGEN EVOLUTION REACTION | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-04-02 | — | — | US | disclosed |
| WO-1999059545-A9 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG INC (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999059545-A1 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-4622078-A | Process for the zinc/calcium phosphatizing of metal surfaces at low treatment temperatures | GERHARD COLLARDIN GMBH (DE) | 1986-11-11 | — | — | US | disclosed |
| US-4337173-A | USED AS OXIDATION CATALYST PARTICULARLY FOR PRODUCING MALEIC ANHYDRIDE | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092381-A1 | BIMETALLIC IRON-VANADIUM OXIDE ELECTROCATALYST FOR OXYGEN EVOLUTION REACTION | FECH, MFAP1, AP2S1 | SLC34A1 615/4885LMNA 3831/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | SLC34A1 46/4885LMNA 1721/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | SLC34A1 550/4885LMNA 733/4885 |
| US-20260148984-A1 | IRON PHOSPHATE MATERIAL AND PREPARATION METHOD THEREFOR, CATHODE MATERIAL, CATHODE SHEET, AND SECONDARY BATTERY | CACNA2D1, CACNA2D3, CACNA2D4 | SLC34A1 18/4885LMNA 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.